Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
This article was originally published in The Gray Sheet
Executive Summary
It takes more than safety and effectiveness data alone for FDA device reviewers to determine how benefits stack up against risks in a pre-market submission, the agency accentuates in new draft guidance.